KB7 Stock Overview
A healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 3/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Solventum Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$54.00 |
| 52 Week High | US$59.50 |
| 52 Week Low | US$51.50 |
| Beta | 0 |
| 1 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -5.26% |
Recent News & Updates
Recent updates
Shareholder Returns
| KB7 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -1.8% | -1.6% | -1.3% |
| 1Y | n/a | -3.2% | 4.0% |
Return vs Industry: Insufficient data to determine how KB7 performed against the German Medical Equipment industry.
Return vs Market: Insufficient data to determine how KB7 performed against the German Market.
Price Volatility
| KB7 volatility | |
|---|---|
| KB7 Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 4.6% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.6% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: KB7 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine KB7's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2023 | 22,000 | Bryan Hanson | www.solventum.com |
Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.
Solventum Corporation Fundamentals Summary
| KB7 fundamental statistics | |
|---|---|
| Market cap | €9.45b |
| Earnings (TTM) | €1.19b |
| Revenue (TTM) | €7.56b |
7.9x
P/E Ratio1.2x
P/S RatioIs KB7 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KB7 income statement (TTM) | |
|---|---|
| Revenue | US$8.20b |
| Cost of Revenue | US$3.47b |
| Gross Profit | US$4.73b |
| Other Expenses | US$3.44b |
| Earnings | US$1.29b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 7.47 |
| Gross Margin | 57.64% |
| Net Profit Margin | 15.73% |
| Debt/Equity Ratio | 215.6% |
How did KB7 perform over the long term?
See historical performance and comparison